Latent TB treatment outcomes in patients with chronic liver disease: A retrospective cohort study
LTBI treatment in patients with CLD is achievable and generally well tolerated despite significant comorbidities. While cirrhosis was associated with lower treatment completion, it did not independently increase DILI risk. Shorter rifamycin-based regimens were safer and better tolerated compared to longer isoniazid-based regimens. Individualized regimen selection and close monitoring are essential to optimizing LTBI treatment outcomes in this high-risk population.
Authors
- Sofia Lopiano
- Eugene J. Kim (ORCID: https://orcid.org/0000-0002-3474-3676)
- Berk Madendere (ORCID: https://orcid.org/0000-0003-0033-6180)
- Isabella Blanchard (ORCID: https://orcid.org/0000-0002-4995-031X)
- Alan Nguyen (ORCID: https://orcid.org/0000-0001-6790-2568)
- Amee Patrawalla (ORCID: https://orcid.org/0000-0002-2297-9446)
- David Rutenberg (ORCID: https://orcid.org/0000-0002-5052-7615)
- Anand Shah (ORCID: https://orcid.org/0000-0002-0573-8448)
- Lilian Tran
Institutions
- Rutgers, The State University of New Jersey (US)
- Moffitt Cancer Center (US)
Publication Details
- Journal
- Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1016/j.jctube.2025.100572
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00